Research progress on individualized treatment of chronic hepatitis C
XU Pei-Qi1,2, HU Chang-Ming1, YE Xiao-Guang3, WU Shang-Wei1,2
1. Guangzhou Kingmed Diagnostics Center, Guangzhou 510330, China; 2. Tianjin Medical University, Tianjin 300070, China; 3. The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China
Abstract:Hepatitis C, caused by infection of hepatitis C virus (HCV), is an acute or chronic infectious disease involved with a significant proportion of population worldwide. In general, 50%-85% of the infections might become chronic hepatitis C or carriers, thereafter developing into cirrhosis and hepatocellular carcinoma. Currently, the standard of care for chronic hepatitis C is pegylated interferon α (PEG-INFα) plus ribavirin (RBV). Nevertheless, about 50% of the patients infected with HCV genotype 1 fail to achieve sustained virological response (SVR) although they share the same or similar diagnosis. A number of clinical studies show that the efficacy of standard of care depent on both virus and host factors. The predictors of SVR on the HCV side include viral load and genotype; on the host side, gender, age, alcohol consumption, fibrosis stage, co-infection with other virus, genetic polymorphisms are included. Among those, the most important elements that may play significant roles in the individualized treatment of HCV infections are the viral load and genotype as well as the variation in the host gene interleukin 28B (IL-28B).
徐佩琦1,2,胡昌明1,叶晓光3,吴尚为1,2. 慢性丙型肝炎个体化治疗研究进展[J]. 微生物与感染
, 2013, 8(3): 186-191.
XU Pei-Qi1,2, HU Chang-Ming1, YE Xiao-Guang3, WU Shang-Wei1,2. Research progress on individualized treatment of chronic hepatitis C. Journal of Microbes and Infections, 2013, 8(3): 186-191.